Data Insights

Risk adjusted net present value: What is the current valuation of Kymera Therapeutics's KT-333?

KT-333 is a small molecule commercialized by Kymera Therapeutics, with a leading Phase I program in Cutaneous T-Cell Lymphoma;Peripheral T-Cell...

Net Present Value Model: Kymera Therapeutics Inc's KT-333

Data Insights

KT-333 by Kymera Therapeutics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...

Likelihood of Approval and Phase Transition Success Rate Model - KT-333 in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

KT-333 by Kymera Therapeutics for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval

KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Kidney Cancer (Renal Cell Cancer). According...

Likelihood of Approval and Phase Transition Success Rate Model - KT-333 in Kidney Cancer (Renal Cell Cancer)

Data Insights

KT-333 by Kymera Therapeutics for Natural Killer Cell Lymphomas: Likelihood of Approval

KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Natural Killer Cell Lymphomas. According to...

Likelihood of Approval and Phase Transition Success Rate Model - KT-333 in Natural Killer Cell Lymphomas

Data Insights

KT-333 by Kymera Therapeutics for T-Cell Lymphomas: Likelihood of Approval

KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for T-Cell Lymphomas. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - KT-333 in T-Cell Lymphomas

Data Insights

KT-333 by Kymera Therapeutics for Solid Tumor: Likelihood of Approval

KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - KT-333 in Solid Tumor

Data Insights

KT-333 by Kymera Therapeutics for Head And Neck Cancer: Likelihood of Approval

KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Head And Neck Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - KT-333 in Head And Neck Cancer

Data Insights

KT-333 by Kymera Therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval

KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - KT-333 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Data Insights

KT-333 by Kymera Therapeutics for Non-Hodgkin Lymphoma: Likelihood of Approval

KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - KT-333 in Non-Hodgkin Lymphoma

Data Insights

KT-333 by Kymera Therapeutics for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval

KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According to...

Likelihood of Approval and Phase Transition Success Rate Model - KT-333 in Peripheral T-Cell Lymphomas (PTCL)

Data Insights

KT-333 by Kymera Therapeutics for Cutaneous T-Cell Lymphoma: Likelihood of Approval

KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Cutaneous T-Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - KT-333 in Cutaneous T-Cell Lymphoma

Data Insights

Risk adjusted net present value: What is the current valuation of Kymera Therapeutics's KT-333?

KT-333 is a small molecule commercialized by Kymera Therapeutics, with a leading Phase I program in Natural Killer Cell Lymphomas....

Net Present Value Model: Kymera Therapeutics Inc's KT-333